Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection
Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.
You may also be interested in...
Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
New medicines under evaluation at the European Medicines Agency.